ARUNDEL, AUSTRALIA / ACCESSWIRE / October 9, 2023 / China Dasheng Biotechnology Co. (OTC PINK:CDBT) advisors that the company has terminated the China Dasheng Biotechnology Co. Consulting Agreement with Kenneth Maciora, Empire Relations Group, Inc. and Empire Relations Holdings LLC.

On July 10, 2023, CDBT entered the China Dasheng Biotechnology Co. Consulting Agreement which had a 3-month period expiring on October 10, 2023, with an upfront fee and an extension of a further 3 months.

On October 5, 2023, CDBT formally terminated the China Dasheng Biotechnology Co. Consulting Agreement with Kenneth Maciora, Empire Relations Group Inc. and Empire Holdings LLC.

/S/ Micheal Nugent
CEO of CDBT

# # #

CDBT. Cycclone Magnetic Engines, Inc.

On April 24, 2023, CDBT entered a Share Exchange Agreement to acquire all of the outstanding shares in Cycclone Magnetic Engines, Inc., the original founding company of the Cycclone Magnetic Engine project.

On September 30, 2022, CDBT and Cycclone Magnetic Engine Developments Limited entered into an Operating Agreement for The Amended Share Exchange Agreement giving effective control of Cycclone Magnetic Engine Developments Limited and the wholly owned subsidiaries.

Cycclone Magnetic Engines is engaged in the development and commercialization of new geometric configuration low carbon emission engines and other clean technology solutions with a view to create technologies that improve efficiency and reduce levels of greenhouse emissions. Cycclone has shareholding, assets, and interests in transport operations in Australia.

Micheal Nugent
mnugent@nugent.com.au
www.cdbtcycclone.com
USA +1 775-580-4544
AUS +61 438 158 688

Safe Harbor Statement
Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Risk factors that could cause actual results to differ materially from those projected in forward-looking statements include, but are not limited to, general business conditions, managing growth, and political and other business risks.

SOURCE: China Dasheng Biotechnology Co.